Skip to content
Shares of Memory chip specialist Micron (MU) trended downwards on Wednesday following the release of the company’s FQ4 results.Micron reported revenue of $6.06 billion, a 24% year-over-year increase and coming in ahead of the estimates by $170 million. Non-GAAP (adjusted) net profit almost doubled from the same quarter last year to clock in just under $1.23 billion, resulting in Non-GAAP EPS of $1.08, above consensus estimates by $0.11.So far, so good. What investors did not like, however, was Micron’s forecast of what’s to come next. For the November quarter, Micron anticipates revenue of $5.2 billion, just under consensus calls for $5.3 billion, while the company’s forecast for non-GAAP EPS of $0.47 at the mid-point is also well below the Street’s $0.68 estimate.Soft near-term gross margins on heightened NAND mix and several DRAM ramps along with the loss of Huawei revenue (which amounted to almost 10% of sales in the quarter) are...
Knight-Swift Transportation announced it plans to cut its carbon emissions in half by the year 2035 and is testing a Freightliner eCascadia electric truck. ...
Knight-Swift Transportation recently set a goal to cut its carbon emissions in half by the year 2035. ...
As investors pile into safe havens like cash and precious metals, a new gold rush is starting in one of the world’s most exciting mining hotspots...
A green light from the FDA can change everything for a healthcare company. This might just be the case for Eton Pharmaceuticals (ETON).On September 29, the company announced that the FDA had given Alkindi Sprinkle, its taste-neutral sprinkle (granule) formulation of hydrocortisone designed as a replacement therapy for pediatric adrenal insufficiency (AI), its stamp of approval.The verdict came on the previously scheduled PDUFA date. Additionally, six clinical studies, including the first and only interventional Phase 3 study of oral hydrocortisone for pediatric AI in neonates to children under eight years of age, served as the basis for the approval. Before the therapy got the FDA approval, oral hydrocortisone was only approved in tablet formulations of 5mg and stronger, with many pediatric patients requiring significantly lower doses. Alkindi Sprinkle will be available in 0.5mg, 1mg, 2mg and 5mg strengths, which will give clinicians flexibility to individualize dosing based on each patient’s needs...
Stock futures opened flat Wednesday evening heading into the first trading day of October and the fourth quarter....
What a ride 2020 has been so far for Nio (NIO). The Chinese EV manufacturer has taken the bull by the horns and has ridden it all the way to massive gains of 427%.There’s no doubt the hype on EV vehicles in 2020 is almost at fever pitch, with investors banking on the sector disrupting the entire auto industry over the coming years. However, as in any emerging industry there will be winners and losers.After initiating coverage of Nio earlier this month, the main pushback for Deutsche bank's Edison Yu from investors concerned the fact Nio “does not create the same level of excitement and loyalty in China that Tesla or the German luxury automakers command.”While Yu concedes that “given NIO is an upstart,” there is some truth to that assertion. The analyst points to recent data that shows “NIO is increasingly perceived by customers as a high-quality premium brand with...
